Collateral License Agreement between GeneLink, Inc. and The University of North Texas Health Science Center at Forth Worth dated July 1, 1996. 2 pages
The Contra Costa California Collateral License Agreement between Gentling, Inc. and The University of North Texas Health Science Center is a legal agreement that outlines the terms and conditions for the use and transfer of intellectual property rights. It allows Gentling, Inc. to utilize certain technologies, patents, or innovations developed by The University of North Texas Health Science Center in Contra Costa, California, in exchange for specific considerations. This specific Collateral License Agreement is established between Gentling, Inc., a biotechnology company specializing in genetic testing and personalized medicine, and The University of North Texas Health Science Center, a renowned educational institution and research center in the field of health sciences. By entering into this agreement, Gentling, Inc. gains access to valuable intellectual property held by The University of North Texas Health Science Center, enabling the company to advance its research and development efforts in Contra Costa, California. The agreement ensures that the utilization of the licensed intellectual property is within the terms and scope defined by the agreement. Some potential types of Contra Costa California Collateral License Agreements between Gentling, Inc. and The University of North Texas Health Science Center could include: 1. Technology Transfer Agreement: This agreement allows Gentling, Inc. to acquire the rights to commercialize specific technologies developed by The University of North Texas Health Science Center in Contra Costa, California. These technologies may range from diagnostic tools to therapeutic methodologies, providing Gentling, Inc. with a competitive edge in the market. 2. Patent License Agreement: This type of agreement grants Gentling, Inc. the use of patented inventions or discoveries developed by The University of North Texas Health Science Center in Contra Costa, California. The license gives the company exclusive rights to manufacture, sell, or utilize the patented technology for a specific period, helping it protect its innovations and expand its product portfolio. 3. Research Collaboration Agreement: This form of agreement encourages a collaborative effort between Gentling, Inc. and The University of North Texas Health Science Center. It outlines the terms for joint research projects, allowing both entities to share resources, expertise, and intellectual property to develop breakthrough innovations in Contra Costa, California. This agreement typically highlights the responsibilities, contributions, and benefits of each party involved. Overall, the Contra Costa California Collateral License Agreement between Gentling, Inc. and The University of North Texas Health Science Center serves as a crucial framework for promoting innovation, driving technological advancements, and fostering mutually beneficial partnerships in the field of health sciences within the Contra Costa, California region.
The Contra Costa California Collateral License Agreement between Gentling, Inc. and The University of North Texas Health Science Center is a legal agreement that outlines the terms and conditions for the use and transfer of intellectual property rights. It allows Gentling, Inc. to utilize certain technologies, patents, or innovations developed by The University of North Texas Health Science Center in Contra Costa, California, in exchange for specific considerations. This specific Collateral License Agreement is established between Gentling, Inc., a biotechnology company specializing in genetic testing and personalized medicine, and The University of North Texas Health Science Center, a renowned educational institution and research center in the field of health sciences. By entering into this agreement, Gentling, Inc. gains access to valuable intellectual property held by The University of North Texas Health Science Center, enabling the company to advance its research and development efforts in Contra Costa, California. The agreement ensures that the utilization of the licensed intellectual property is within the terms and scope defined by the agreement. Some potential types of Contra Costa California Collateral License Agreements between Gentling, Inc. and The University of North Texas Health Science Center could include: 1. Technology Transfer Agreement: This agreement allows Gentling, Inc. to acquire the rights to commercialize specific technologies developed by The University of North Texas Health Science Center in Contra Costa, California. These technologies may range from diagnostic tools to therapeutic methodologies, providing Gentling, Inc. with a competitive edge in the market. 2. Patent License Agreement: This type of agreement grants Gentling, Inc. the use of patented inventions or discoveries developed by The University of North Texas Health Science Center in Contra Costa, California. The license gives the company exclusive rights to manufacture, sell, or utilize the patented technology for a specific period, helping it protect its innovations and expand its product portfolio. 3. Research Collaboration Agreement: This form of agreement encourages a collaborative effort between Gentling, Inc. and The University of North Texas Health Science Center. It outlines the terms for joint research projects, allowing both entities to share resources, expertise, and intellectual property to develop breakthrough innovations in Contra Costa, California. This agreement typically highlights the responsibilities, contributions, and benefits of each party involved. Overall, the Contra Costa California Collateral License Agreement between Gentling, Inc. and The University of North Texas Health Science Center serves as a crucial framework for promoting innovation, driving technological advancements, and fostering mutually beneficial partnerships in the field of health sciences within the Contra Costa, California region.